The Fibronectin-Binding Protein EfbA Contributes to Pathogenesis and Protects against Infective Endocarditis Caused by Enterococcus faecalis

Infection and Immunity
Kavindra V SinghBarbara E Murray

Abstract

EfbA is a PavA-like fibronectin adhesin of Enterococcus faecalis previously shown to be important in experimental urinary tract infection. Here, we expressed and purified the E. faecalis OG1RF EfbA and confirmed that this protein binds with high affinity to immobilized fibronectin, collagen I, and collagen V. We constructed an efbA deletion mutant and demonstrated that its virulence was significantly attenuated (P < 0.0006) versus the wild type in a mixed inoculum rat endocarditis model. Furthermore, efbA deletion resulted in diminished ability to bind fibronectin (P < 0.0001) and reduced biofilm (P < 0.001). Reintroduction of efbA into the original chromosomal location restored virulence, adherence to fibronectin, and biofilm formation to wild-type levels. Finally, vaccination of rats with purified recombinant EfbA protein protected against OG1RF endocarditis (P = 0.008 versus control). Taken together, our results demonstrate that EfbA is an important factor involved in E. faecalis endocarditis and that rEfbA immunization is effective in preventing such infection, likely by interfering with bacterial adherence.

References

Jul 1, 1990·The Journal of Clinical Investigation·J H LowranceW A Simpson
Jan 1, 1990·Clinical Microbiology Reviews·B E Murray
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M L Fernández-GuerreroM de Górgolas
Nov 27, 1996·Molecular & General Genetics : MGG·K LeenhoutsJ Kok
Mar 9, 2000·The New England Journal of Medicine·B E Murray
Sep 24, 2002·Journal of Cell Science·Roumen Pankov, Kenneth M Yamada
Jan 26, 1963·JAMA : the Journal of the American Medical Association·A A ANGRIST, M OKA
Apr 23, 2005·Infection and Immunity·Daniela PrachtSven Hammerschmidt
Jun 24, 2005·JAMA : the Journal of the American Medical Association·Imad M TleyjehLarry M Baddour
Oct 4, 2006·The Journal of Clinical Investigation·Sreedhar R NallapareddyBarbara E Murray
May 10, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E GiannitsiotiUNKNOWN Hellenic Endocarditis Study Group
Mar 25, 2010·Molecular Oral Microbiology·A KadiogluH F Jenkinson
Sep 23, 2011·Cold Spring Harbor Perspectives in Biology·Wolfgang Bergmeier, Richard O Hynes
Mar 17, 2012·Nature Reviews. Microbiology·Cesar A Arias, Barbara E Murray
Feb 9, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nuria Fernández-HidalgoAlbert Pahissa
Dec 18, 2013·Nature Reviews. Microbiology·Timothy J FosterMagnus Höök
Jan 24, 2014·Infection and Immunity·Kenneth L PinkstonBarrett R Harvey
Aug 29, 2014·Current Infectious Disease Reports·Masayuki NigoBarbara E Murray
Dec 3, 2014·The Journal of Hospital Infection·A GhoshUNKNOWN Hamilton Health Sciences Infection Prevention and Control Team

❮ Previous
Next ❯

Citations

Mar 21, 2017·Current Opinion in Infectious Diseases·Garth Dixon, Georgi Christov
Jan 20, 2017·Virulence·H M Sharon GohKimberly A Kline
Nov 9, 2016·Antimicrobial Agents and Chemotherapy·Maria Camila MontealegreBarbara E Murray
Jun 2, 2017·The Open Microbiology Journal·Kristian T MadsenMichael Kemp
Nov 23, 2018·Acta Microbiologica Et Immunologica Hungarica·Asieh TajiMohammad Motamedifar
Jul 1, 2020·The Journal of Infectious Diseases·Armand O BrownDanielle A Garsin
Mar 24, 2017·Infection & chemotherapy·Hamid HeidariMohammad Motamedifar
Nov 30, 2019·Cells·Pietro SpezialeGiampiero Pietrocola
Dec 2, 2020·Molecular Cell·Caillan Crowe-McAuliffeVasili Hauryliuk
Jul 13, 2019·Microbiology Spectrum·Elizabeth FioreMichael S Gilmore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.